Novavax : is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy

Published: 2025-01-13 08:15:05 ET NVAX

By Ruxandra Draghia-Akli, MD, PhD, Executive Vice President, Head of R&D and Elaine O'Hara, Executive Vice President, Chief Strategy Officer

As we enter the new year, Novavax is embarking on an ambitious new corporate growth strategy to maximize the impact of our cutting-edge technology. We are focused on forging strategic partnerships for both our early- and late-stage research and development (R&D) assets and our Matrix-M™ adjuvant with the goal of driving vaccine innovation that protects the health of people.

Our Innovative Technology Platform

Novavax's technology platform combined with our deep vaccine expertise is the fuel for future innovation and partnerships. The unique platform features two key elements:

Our technology platform allows Novavax to focus on driving vaccine innovation to tackle global health challenges and create significant value.

Disciplined Pipeline Diversification

We are actively advancing our pipeline - both late- and early-stage programs - with a focus on high-value assets in areas with unmet medical need, compelling scientific rationale and strong commercial opportunity. We intend to develop our early-stage pipeline using a disciplined and capital-efficient approach. Our R&D investment strategy will allow us to place smart, lower-cost bets on the highest-value programs, both within infectious disease and beyond, with the intent of partnering these assets at proof of concept and shifting late-stage development costs to our partners to finalize clinical development.

These rigorous principles guide our selection process:

To maximize value creation as we execute against these principles, we will prioritize programs based on scientific rationale, rapid proof-of-concept generation, unmet medical need and attractiveness to potential partners in the competitive landscape.

A Model for Partnership

We are shifting from developing and commercializing our COVID-19 vaccine to focusing on what we do best: R&D with our technology platform combined with the business acumen to forge successful development and commercialization partnerships.

The first proof point of this new strategy was an agreement we announced with Sanofi last year. Beginning in 2025, Sanofi will lead the commercialization of our COVID-19 vaccine. In addition to milestones and royalties for the stand-alone COVID-19 vaccine, the agreement also includes additional potential revenue streams from combination products developed by Sanofi using our COVID-19 vaccine and other Sanofi vaccines developed using Matrix-M. The structure of the agreement including upfront payments, potential milestone payments and ongoing tiered product royalties serves as a model for future collaborations aimed at enhancing stakeholder value and broadening access to our technology.

Future Partnership Opportunities and Commitment to Health

As our early-stage pipeline progresses, our goal is to create partnership and collaboration opportunities and maximize the value of these R&D assets AND Matrix-M alone through:

By focusing on our high-impact, diversified R&D pipeline and strategic collaborations, Novavax is well-positioned to expand access to our technology, deliver transformative advancements for global health and create sustained value for years to come.

For inquiries on specific partnership opportunities, please visit our website.

References

Disclaimer

Novavax Inc. published this content on January 13, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 13, 2025 at 13:14:06.288.